Reduced vision secondary to pigmented cellular membranes on silicone intraocular lenses.
OBJECTIVE
Visually significant, pigmented cellular membranes may form on intraocular lenses after implantation. We studied a series of patients to determine the onset, visual significance, treatment, and recurrent nature of these pigmented membranes in patients who underwent surgery with silicone lens implantation.


METHODS
In nine eyes (eight patients) with visually significant pigmented cellular membranes on their Allergan Medical Optics (Irvine, California) silicone intraocular lenses (model SI18NGB or SI26NB), eight underwent combined phacoemulsification, intraocular lens implantation, and trabeculectomy; one underwent phacoemulsification and lens implantation only. We reviewed medical records to identify preoperative, operative, and postoperative similarities and differences in care. Clinical examinations and slit-lamp photographs, over an average of 21.3 +/- 7.2 months (range, 11 to 31 months), documented the effects of different treatment modalities.


RESULTS
The patients sought treatment ten to 20 weeks (mean, 15 weeks) postoperatively. Except for the cellular membranes, each eye was without evidence of inflammation or cystoid macular edema. Subjective complaints decreased, and best-corrected Snellen visual acuity improved with topical corticosteroid therapy alone. Pretreatment best-corrected visual acuities ranged from 20/40 to 20/400 (mean, 20/70 using Snellen fractions) and improved two to eight (mean, five) Snellen lines, to a range of 20/20 to 20/50 (mean, 20/25). All nine eyes had recurrence of the membranes after treatment terminated and required a maintenance regimen of corticosteroid eyedrops.


CONCLUSIONS
The pigmented cellular membranes observed on these silicone lenses were visually significant to each patient. The membranes resolved and visual acuity improved with topical corticosteroid treatment alone but recurred in all patients on cessation of treatment.
Carlson
D W
DW
Wilford Hall Medical Center, San Antonio, Texas, USA.
Barad
J P
JP
Parsons
M R
MR
D000368:Aged; D000369:Aged, 80 and over; D002462:Cell Membrane / Q000473:pathology; D005260:Female; D005549:Foreign-Body Reaction / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005902:Glaucoma, Open-Angle / Q000601:surgery; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D053685:Laser Therapy; D007910:Lenses, Intraocular / Q000009:adverse effects*; D008297:Male; D009883:Ophthalmic Solutions; D018918:Phacoemulsification; D010858:Pigmentation; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D012826:Silicone Elastomers / Q000009:adverse effects*; D014130:Trabeculectomy; D014786:Vision Disorders / Q000209:etiology*; D014792:Visual Acuity
D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D012826:Silicone Elastomers; D011239:Prednisolone